
|Articles|January 1, 2003
Injectable Silicone Shows Promisefor Treatment of HIV-associated Facial Lipoatrophy
Chicago -- Off-label experience using injectable silicone (Silikon 1000) in an investigational protocol indicates it is a highly effective and, thus far, very safe modality for treating facial lipoatrophy in HIV-infected patients, Derek H. Jones, M.D., said at the annual meeting of the American Society for Dermatologic Surgery.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
2
Off-Label Case Series: Topical Roflumilast for Mild HS
3
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
4
Comparative Analysis Positions Zasocitinib Among Next-Generation TYK2 Inhibitors
5


















